NCT05566990View on ClinicalTrials.gov

A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj.10% in Primary Immune Thrombocytopenia (ITP)

PHASE3CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

July 19, 2019

Primary Completion Date

June 3, 2021

Study Completion Date

November 26, 2021

Conditions
Immune Thrombocytopenia
Interventions
BIOLOGICAL

LIV-GAMMA SN Inj.10%

LIV-GAMMA SN Inj. 10% is administered intravenously at a dose of 1 g/kg daily for 2 consecutive days to patients with primary immune thrombocytopenia.

Trial Locations (11)

Unknown

Dong-A University Hospital, Busan

Kosin University Gospel Hospital, Busan

Pusan National University Hospital, Busan

Kyungpook National University Hospital, Daegu

Chungnam National University Hospital, Daejeon

Gachon University Gil Medical Center, Incheon

Seoul National University Bundang Hospital, Seongnam

Samsung Medical Center, Seoul

Seoul National University Hospital, Seoul

Severance Hospital, Seoul

The Catholic University of Korea, Seoul ST. Mary's Hospital, Seoul

All Listed Sponsors
lead

SK Plasma Co., Ltd.

INDUSTRY

NCT05566990 - A Clinical Study to Evaluate the Efficacy and Safety of LIV-GAMMA SN Inj.10% in Primary Immune Thrombocytopenia (ITP) | Biotech Hunter | Biotech Hunter